N/A
N=120
Insertion of an Intrauterine Device (IUD) After Medical Abortion
Intrauterine Device Expulsion · Medical Abortion · Induced Abortion
Bottom Line
View on ClinicalTrials.gov: NCT00621543 ↗Enrolled (actual)
120
Serious AEs
0.0%
Results posted
Jul 2011
Primary outcome: Primary: Percentage of Women With Expulsion of an Intrauterine Device (IUD) Placed After Medical Abortion. — 4 percentage of participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- IUD insertion [Copper T-380A or Levonorgestrel (intrauterine system) IUS] (Device)
- Age
- Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Boston University
- Primary completion
- May 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Women With Expulsion of an Intrauterine Device (IUD) Placed After Medical Abortion. |
4 | — |
| SECONDARY Percentage of Women Continuing IUD Use at 3 Months |
80. | — |
Summary
The purpose of this study is to determine the expulsion and continuation rate of an intruterine device (IUD) placed immediately after medical abortion.
Our hypothesis is that immediate-placement of an IUD after completed medical abortion will have a similar expulsion and continuation rate to traditional placement (4-6 weeks after pregnancy).
Eligibility Criteria
Inclusion Criteria
- Women who completed a medical abortion in the last 14 days
- At least 18 years old.
- Desiring long-term contraception with an IUD.
- Able and willing to give consent for participation in research.
- Gonorrhea and chlamydia screen negative within 60 days of entry to study.
- Willing to comply with the study requirements.
- Accessible by telephone.
Exclusion Criteria
- Had pelvic inflammatory disease or a septic abortion within the past 3 months or gonorrheal or chlamydial infection in the last 60 days.
- Allergy to copper, or Wilson's disease (for Paragard; may have Mirena)
- Intracavitary of symptomatic uterine fibroids.
- Ovarian, cervical or endometrial cancer.
- Severe anemia (defined as hgb < 8).
Data sourced from ClinicalTrials.gov (NCT00621543). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.